Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus

Authors: Kazunori Morita, Junji Saruwatari, Haruna Miyagawa, Yoshihiro Uchiyashiki, Kentaro Oniki, Misaki Sakata, Ayami Kajiwara, Akira Yoshida, Hideaki Jinnouchi, Kazuko Nakagawa

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

Mitochondrial aldehyde dehydrogenase 2 (ALDH2) detoxifies reactive aldehydes in the micro- and macrovasculature. These substrates, including methylglyoxal and 4-hydroxynonenal formed from glucose and lipids, cause protein carbonylation and mitochondrial dysfunction, forming advanced glycation end products (AGEs). The present study aimed to confirm the association between the inactive ALDH2*2 allele and diabetic retinopathy (DR).

Methods

A retrospective longitudinal analysis was conducted, among 234 Japanese patients with type 2 diabetes mellitus (DM) (156 males and 78 females) who had no DR signs at baseline and were treated for more than half a year. The ALDH2*1/*2 alleles were determined using a real-time TaqMan allelic discrimination assay. Multivariate-adjusted hazard ratios (HRs) and 95% confidential intervals (CIs) for the cumulative incidence of the development of DR were examined using a Cox proportional hazard model, taking drinking habits and the serum γ-glutamyltransferase (GGT) level into consideration.

Results

The frequency of the ALDH2*2 allele was 22.3%. Fifty-two subjects cumulatively developed DR during the follow-up period of 5.5 ± 2.5 years. The ALDH2*2 allele carriers had a significantly higher incidence of DR than the non-carriers (HR: 1.92; P = 0.02). The incidence of DR was significantly higher in the drinkers with the ALDH2*2 allele than in those with the ALDH2*1/*1 genotype (HR: 2.61; P = 0.03), while the incidence of DR in the non-drinkers did not differ significantly between the ALDH2 genotype groups (P > 0.05). The incidence of DR was significantly higher in the ALDH2*2 allele carriers with a high GGT level than in the non-carriers with a high or low GGT level (HR: 2.45; P = 0.03; and HR: 2.63; P = 0.03, respectively).

Conclusions

To the best of our knowledge, this is the first report of a significant association between the ALDH2*2 allele and the incidence of DR. These findings provide additional evidence that ALDH2 protects both microvasculature and macrovasculature against reactive aldehydes generated under conditions of sustained oxidative stress, although further investigations in larger cohorts are needed to verify the results.
Appendix
Available only for authorised users
Literature
2.
go back to reference Rosenson RS, Fioretto P, Dodson PM: Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis. 2011, 218 (1): 13-18. 10.1016/j.atherosclerosis.2011.06.029.CrossRefPubMed Rosenson RS, Fioretto P, Dodson PM: Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis. 2011, 218 (1): 13-18. 10.1016/j.atherosclerosis.2011.06.029.CrossRefPubMed
3.
go back to reference Ceriello A, Ihnat MA, Thorpe JE: Clinical review 2: The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab. 2009, 94 (2): 410-415. 10.1210/jc.2008-1824.CrossRefPubMed Ceriello A, Ihnat MA, Thorpe JE: Clinical review 2: The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab. 2009, 94 (2): 410-415. 10.1210/jc.2008-1824.CrossRefPubMed
4.
go back to reference O’Brien PJ, Siraki AG, Shangari N: Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol. 2005, 35 (7): 609-662. 10.1080/10408440591002183.CrossRefPubMed O’Brien PJ, Siraki AG, Shangari N: Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol. 2005, 35 (7): 609-662. 10.1080/10408440591002183.CrossRefPubMed
5.
go back to reference Yang K, Qiang D, Delaney S, Mehta R, Bruce WR, O’Brien PJ: Differences in glyoxal and methylglyoxal metabolism determine cellular susceptibility to protein carbonylation and cytotoxicity. Chem Biol Interact. 2011, 191 (1–3): 322-329.CrossRefPubMed Yang K, Qiang D, Delaney S, Mehta R, Bruce WR, O’Brien PJ: Differences in glyoxal and methylglyoxal metabolism determine cellular susceptibility to protein carbonylation and cytotoxicity. Chem Biol Interact. 2011, 191 (1–3): 322-329.CrossRefPubMed
6.
go back to reference Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, et al: Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011, 43 (6): 531-538. 10.1038/ng.834.PubMedCentralCrossRefPubMed Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, et al: Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011, 43 (6): 531-538. 10.1038/ng.834.PubMedCentralCrossRefPubMed
7.
go back to reference Nose J, Saito A, Kamatani N: Statistical analysis of the associations between polymorphisms within aldehyde dehydrogenase 2 (ALDH2), and quantitative and qualitative traits extracted from a large-scale database of Japanese single-nucleotide polymorphisms (SNPs). J Hum Genet. 2008, 53 (5): 425-438. 10.1007/s10038-008-0266-2.CrossRefPubMed Nose J, Saito A, Kamatani N: Statistical analysis of the associations between polymorphisms within aldehyde dehydrogenase 2 (ALDH2), and quantitative and qualitative traits extracted from a large-scale database of Japanese single-nucleotide polymorphisms (SNPs). J Hum Genet. 2008, 53 (5): 425-438. 10.1007/s10038-008-0266-2.CrossRefPubMed
8.
go back to reference Nakagawa T, Kajiwara A, Saruwatari J, Hamamoto A, Kaku W, Oniki K, Mihara S, Ogata Y, Nakagawa K: The combination of mitochondrial low enzyme-activity aldehyde dehydrogenase 2 allele and superoxide dismutase 2 genotypes increases the risk of hypertension in relation to alcohol consumption. Pharmacogenet Genomics. 2013, 23 (1): 34-37. 10.1097/FPC.0b013e32835b1707.CrossRefPubMed Nakagawa T, Kajiwara A, Saruwatari J, Hamamoto A, Kaku W, Oniki K, Mihara S, Ogata Y, Nakagawa K: The combination of mitochondrial low enzyme-activity aldehyde dehydrogenase 2 allele and superoxide dismutase 2 genotypes increases the risk of hypertension in relation to alcohol consumption. Pharmacogenet Genomics. 2013, 23 (1): 34-37. 10.1097/FPC.0b013e32835b1707.CrossRefPubMed
10.
go back to reference Turgut O, Tandogan I: Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. J Atheroscler Thromb. 2011, 18 (3): 177-181. 10.5551/jat.6189.CrossRefPubMed Turgut O, Tandogan I: Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. J Atheroscler Thromb. 2011, 18 (3): 177-181. 10.5551/jat.6189.CrossRefPubMed
11.
go back to reference McKillop AM, Flatt PR: Emerging applications of metabolomic and genomic profiling in diabetic clinical medicine. Diabetes Care. 2011, 34 (12): 2624-2630. 10.2337/dc11-0837.PubMedCentralCrossRefPubMed McKillop AM, Flatt PR: Emerging applications of metabolomic and genomic profiling in diabetic clinical medicine. Diabetes Care. 2011, 34 (12): 2624-2630. 10.2337/dc11-0837.PubMedCentralCrossRefPubMed
12.
go back to reference Chen YC, Peng GS, Tsao TP, Wang MF, Lu RB, Yin SJ: Pharmacokinetic and pharmacodynamic basis for overcoming acetaldehyde-induced adverse reaction in Asian alcoholics, heterozygous for the variant ALDH2*2 gene allele. Pharmacogenet Genomics. 2009, 19 (8): 588-599. 10.1097/FPC.0b013e32832ecf2e.CrossRefPubMed Chen YC, Peng GS, Tsao TP, Wang MF, Lu RB, Yin SJ: Pharmacokinetic and pharmacodynamic basis for overcoming acetaldehyde-induced adverse reaction in Asian alcoholics, heterozygous for the variant ALDH2*2 gene allele. Pharmacogenet Genomics. 2009, 19 (8): 588-599. 10.1097/FPC.0b013e32832ecf2e.CrossRefPubMed
13.
go back to reference Li H, Borinskaya S, Yoshimura K, Kal’ina N, Marusin A, Stepanov VA, Qin Z, Khaliq S, Lee MY, Yang Y, et al: Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. Ann Hum Genet. 2009, 73 (Pt 3): 335-345.PubMedCentralCrossRefPubMed Li H, Borinskaya S, Yoshimura K, Kal’ina N, Marusin A, Stepanov VA, Qin Z, Khaliq S, Lee MY, Yang Y, et al: Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. Ann Hum Genet. 2009, 73 (Pt 3): 335-345.PubMedCentralCrossRefPubMed
14.
15.
go back to reference Guo YJ, Chen L, Bai YP, Li L, Sun J, Zhang GG, Yang TL, Xia J, Li YJ, Chen XP: The ALDH2 Glu504Lys polymorphism is associated with coronary artery disease in Han Chinese: Relation with endothelial ADMA levels. Atherosclerosis. 2010, 211 (2): 545-550. 10.1016/j.atherosclerosis.2010.03.030.CrossRefPubMed Guo YJ, Chen L, Bai YP, Li L, Sun J, Zhang GG, Yang TL, Xia J, Li YJ, Chen XP: The ALDH2 Glu504Lys polymorphism is associated with coronary artery disease in Han Chinese: Relation with endothelial ADMA levels. Atherosclerosis. 2010, 211 (2): 545-550. 10.1016/j.atherosclerosis.2010.03.030.CrossRefPubMed
16.
go back to reference Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY: The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol. 2011, 10: 16-10.1186/1475-2840-10-16.PubMedCentralCrossRefPubMed Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY: The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol. 2011, 10: 16-10.1186/1475-2840-10-16.PubMedCentralCrossRefPubMed
17.
go back to reference Yokoyama A, Mizukami T, Matsui T, Yokoyama T, Kimura M, Matsushita S, Higuchi S, Maruyama K: Genetic Polymorphisms of Alcohol Dehydrogenase-1B and Aldehyde Dehydrogenase-2 and Liver Cirrhosis, Chronic Calcific Pancreatitis, Diabetes Mellitus, and Hypertension Among Japanese Alcoholic Men. Alcohol Clin Exp Res. 2013, 37 (8): 1391-1401. 10.1111/acer.12108.CrossRefPubMed Yokoyama A, Mizukami T, Matsui T, Yokoyama T, Kimura M, Matsushita S, Higuchi S, Maruyama K: Genetic Polymorphisms of Alcohol Dehydrogenase-1B and Aldehyde Dehydrogenase-2 and Liver Cirrhosis, Chronic Calcific Pancreatitis, Diabetes Mellitus, and Hypertension Among Japanese Alcoholic Men. Alcohol Clin Exp Res. 2013, 37 (8): 1391-1401. 10.1111/acer.12108.CrossRefPubMed
18.
go back to reference Lee CC, Stolk RP, Adler AI, Patel A, Chalmers J, Neal B, Poulter N, Harrap S, Woodward M, Marre M, et al: Association between alcohol consumption and diabetic retinopathy and visual acuity-the AdRem Study. Diabet Med. 2010, 27 (10): 1130-1137. 10.1111/j.1464-5491.2010.03080.x.CrossRefPubMed Lee CC, Stolk RP, Adler AI, Patel A, Chalmers J, Neal B, Poulter N, Harrap S, Woodward M, Marre M, et al: Association between alcohol consumption and diabetic retinopathy and visual acuity-the AdRem Study. Diabet Med. 2010, 27 (10): 1130-1137. 10.1111/j.1464-5491.2010.03080.x.CrossRefPubMed
19.
go back to reference Wang S, Wang JJ, Wong TY: Alcohol and eye diseases. Surv Ophthalmol. 2008, 53 (5): 512-525. 10.1016/j.survophthal.2008.06.003.CrossRefPubMed Wang S, Wang JJ, Wong TY: Alcohol and eye diseases. Surv Ophthalmol. 2008, 53 (5): 512-525. 10.1016/j.survophthal.2008.06.003.CrossRefPubMed
20.
go back to reference Kloner RA, Rezkalla SH: To drink or not to drink? That is the question. Circulation. 2007, 116 (11): 1306-1317. 10.1161/CIRCULATIONAHA.106.678375.CrossRefPubMed Kloner RA, Rezkalla SH: To drink or not to drink? That is the question. Circulation. 2007, 116 (11): 1306-1317. 10.1161/CIRCULATIONAHA.106.678375.CrossRefPubMed
21.
go back to reference Vasdev S, Gill V, Singal PK: Beneficial effect of low ethanol intake on the cardiovascular system: possible biochemical mechanisms. Vasc Health Risk Manag. 2006, 2 (3): 263-276. 10.2147/vhrm.2006.2.3.263.PubMedCentralCrossRefPubMed Vasdev S, Gill V, Singal PK: Beneficial effect of low ethanol intake on the cardiovascular system: possible biochemical mechanisms. Vasc Health Risk Manag. 2006, 2 (3): 263-276. 10.2147/vhrm.2006.2.3.263.PubMedCentralCrossRefPubMed
22.
go back to reference Beulens JW, Kruidhof JS, Grobbee DE, Chaturvedi N, Fuller JH, Soedamah-Muthu SS: Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study. Diabetologia. 2008, 51 (9): 1631-1638. 10.1007/s00125-008-1091-z.CrossRefPubMed Beulens JW, Kruidhof JS, Grobbee DE, Chaturvedi N, Fuller JH, Soedamah-Muthu SS: Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study. Diabetologia. 2008, 51 (9): 1631-1638. 10.1007/s00125-008-1091-z.CrossRefPubMed
23.
go back to reference Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD: Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol. 2012, 57 (5): 1083-1089. 10.1016/j.jhep.2012.06.034.CrossRefPubMed Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD: Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol. 2012, 57 (5): 1083-1089. 10.1016/j.jhep.2012.06.034.CrossRefPubMed
24.
go back to reference Onat A, Can G, Ornek E, Cicek G, Ayhan E, Dogan Y: Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012, 20 (4): 842-848. 10.1038/oby.2011.136.CrossRef Onat A, Can G, Ornek E, Cicek G, Ayhan E, Dogan Y: Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012, 20 (4): 842-848. 10.1038/oby.2011.136.CrossRef
25.
go back to reference Lee DH, Jacobs DR, Gross M, Steffes M: Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2005, 51 (7): 1185-1191. 10.1373/clinchem.2004.045872.CrossRefPubMed Lee DH, Jacobs DR, Gross M, Steffes M: Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2005, 51 (7): 1185-1191. 10.1373/clinchem.2004.045872.CrossRefPubMed
26.
go back to reference Arkkila PE, Koskinen PJ, Kantola IM, Ronnemaa T, Seppanen E, Viikari JS: Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Res Clin Pract. 2001, 52 (2): 113-118. 10.1016/S0168-8227(00)00241-2.CrossRefPubMed Arkkila PE, Koskinen PJ, Kantola IM, Ronnemaa T, Seppanen E, Viikari JS: Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Res Clin Pract. 2001, 52 (2): 113-118. 10.1016/S0168-8227(00)00241-2.CrossRefPubMed
27.
go back to reference Xu F, Chen Y, Lv R, Zhang H, Tian H, Bian Y, Feng J, Sun Y, Li R, Wang R, et al: ALDH2 genetic polymorphism and the risk of type II diabetes mellitus in CAD patients. Hypertens Res. 2010, 33 (1): 49-55. 10.1038/hr.2009.178.CrossRefPubMed Xu F, Chen Y, Lv R, Zhang H, Tian H, Bian Y, Feng J, Sun Y, Li R, Wang R, et al: ALDH2 genetic polymorphism and the risk of type II diabetes mellitus in CAD patients. Hypertens Res. 2010, 33 (1): 49-55. 10.1038/hr.2009.178.CrossRefPubMed
Metadata
Title
Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus
Authors
Kazunori Morita
Junji Saruwatari
Haruna Miyagawa
Yoshihiro Uchiyashiki
Kentaro Oniki
Misaki Sakata
Ayami Kajiwara
Akira Yoshida
Hideaki Jinnouchi
Kazuko Nakagawa
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-132

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.